Molecular Advances in Cholestatic Liver Diseases

Area of Science:

• Hepatology
• Medical Genetics
• Molecular Biology

Background:

• Cholestatic liver diseases stem from diverse genetic causes, including defects in bile acid synthesis, transport, and duct development.
• Key genes implicated in cholestasis include JAG1, ATP8B1, ABCB11, ABCB4, SERPINA1, and CFTR, associated with conditions like Alagille syndrome and familial intrahepatic cholestasis.
• Drug-induced cholestasis can arise from genetic predispositions affecting hepatic drug metabolism and transporter function.

Purpose of the Study:

• To review the expanding landscape of genetically defined cholestatic liver diseases.
• To highlight the role of genetic mutations in both inherited and drug-induced cholestasis.
• To emphasize the diagnostic utility of comprehensive gene panels.

Main Methods:

• Review of multi-institutional studies identifying frequent mutations in cholestasis.
• Analysis of genetic defects affecting bile acid metabolism and hepatocellular transporters.
• Discussion of the impact of genetic mutations on drug-induced cholestasis.

Main Results:

• Mutations in JAG1, SERPINA1, and CFTR cause Alagille syndrome, alpha-1 antitrypsin deficiency, and cystic fibrosis.
• Mutations in ATP8B1, ABCB11, and ABCB4 lead to a spectrum of intrahepatic cholestasis disorders.
• Comprehensive gene panels facilitate rapid diagnosis and identification of novel cholestasis-associated genes.

Conclusions:

• Genetic testing is crucial for diagnosing a wide range of cholestatic liver diseases.
• Understanding genetic underpinnings aids in managing inherited and drug-induced cholestasis.
• Advances in genetic panels improve diagnostic accuracy and facilitate research into novel causative variants.